ATRX and cancer: Whole genome sequencing (WGS) studies have identified additional mutations not detectable by WES such as intronic translocations impacting TP53 and other cancer genes, supporting the notion that virtually all OS tumors bear inactivating TP53 mutations (95%) and that other driver mutations such as DLG2 (53%), ATRX (29%), RB1 (29%), and MDM2 (3%) are also more commonly altered6.